体内
流式细胞术
心肌梗塞
药品
化学
药理学
心脏病学
体外
个性化医疗
内科学
细胞仪
医学
生物信息学
免疫学
生物
生物化学
生物技术
作者
Yue Chen,Qiong Zhan,Jian Zhang,Wei Wang,Bee Luan Khoo,Zhen Liu,Siqi Wei,Junxin Niu,Jun Xu,Chunquan Yu,Xiumei Hu,Qing Liu,Jongyoon Han,Shuwen Liu,Lihong Liu
标识
DOI:10.1016/j.aca.2022.340151
摘要
The drug-induced diverse response among patients is a severe problem for improving hemorheological character. However, there is no validated method for personalized therapy to the best of our knowledge. Here, we apply a gravity-driven deformability cytometry platform (GD-DCP) to profile the drug response of the red cell deformability (RCD) at the single-cell level using pentoxifylline (PTX) as a model drug, the effect of different concentrations of PTX (0, 2, 20, 200 μg mL-1, the clinical dosage of PTX is 20 μg mL-1) on RCD in patients with cardiovascular disease was explored. Based on the GD-DCP, about 38 and 56% of the acute phase of acute myocardial infarction (AMI) patients in the acute phase and coronary heart disease (CHD) patients respond positively to PTX, respectively, indicating that PTX has a strong patient dependency on RCD. Moreover, RCD is observed to be significantly inversely correlated with the activation of membrane protein kinase C (PKC) as well as the concentration of Ca2+ (both P < 0.001). The results of animal experiments show that the protective effects of PTX on myocardial ischemia rats have substantial individual variation, too. It is noted that the effect of PTX is highly consistent between RCD in vitro and in vivo outcomes (blood viscosity, myocardial injury, and electrocardiogram (ECG)) in the same rat. All these new findings suggest that the GD-DCP is a promising method that uses deformability in vitro as one of the important criteria in personalized medicine, and our study provides unique insight into the individual-dependent mechanisms of PTX for improving RCD.
科研通智能强力驱动
Strongly Powered by AbleSci AI